These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3033218)

  • 1. Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol.
    Beardsley PM; Scimeca JA; Martin BR
    J Pharmacol Exp Ther; 1987 May; 241(2):521-6. PubMed ID: 3033218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol.
    Weissman A; Milne GM; Melvin LS
    J Pharmacol Exp Ther; 1982 Nov; 223(2):516-23. PubMed ID: 6290642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys.
    Gold LH; Balster RL; Barrett RL; Britt DT; Martin BR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):479-86. PubMed ID: 1323651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoids. I. Behavioral effects.
    Stark P; Dews PB
    J Pharmacol Exp Ther; 1980 Jul; 214(1):124-30. PubMed ID: 6771386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
    Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
    Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dependence on tetrahydrocannabinol in rhesus monkeys.
    Beardsley PM; Balster RL; Harris LS
    J Pharmacol Exp Ther; 1986 Nov; 239(2):311-9. PubMed ID: 3021952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests.
    Schulze GE; McMillan DE; Bailey JR; Scallet A; Ali SF; Slikker W; Paule MG
    J Pharmacol Exp Ther; 1988 Apr; 245(1):178-86. PubMed ID: 2834536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of cannabinoids in the elevated plus maze.
    Onaivi ES; Green MR; Martin BR
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1002-9. PubMed ID: 2162942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of delta 9-THC carbamate.
    Little PJ; Kaplan NC; Martin BR
    Alcohol Drug Res; 1987; 7(5-6):517-23. PubMed ID: 3040025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
    Pugh G; Smith PB; Dombrowski DS; Welch SP
    J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Nov; 446():1-317. PubMed ID: 12594529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of systemic and intraventricular administration of cannabinoids on schedule-controlled responding in the squirrel monkey.
    Carney JM; Balster RL; Martin BR; Harris LS
    J Pharmacol Exp Ther; 1979 Sep; 210(3):399-404. PubMed ID: 113528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice.
    Jardinaud F; Roques BP; Noble F
    Behav Brain Res; 2006 Oct; 173(2):255-61. PubMed ID: 16884789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of drugs on behavior in pigeons tolerant to delta 9-tetrahydrocannabinol.
    McMillan DE; Leander JD; Dudley KH
    J Pharmacol Exp Ther; 1980 Jan; 212(1):85-90. PubMed ID: 7351628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine.
    Cheng HY; Laviolette SR; van der Kooy D; Penninger JM
    Eur J Neurosci; 2004 Jun; 19(11):3033-41. PubMed ID: 15182311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of postweaning administration of delta-9-tetrahydrocannabinol (THC) on adult behavioral and neuroendocrine function in Sprague-Dawley and Fischer-344 rats.
    Mokler DJ; Robinson SE; Johnson JH; Hong JS; Rosecrans JA
    Neurobehav Toxicol Teratol; 1986; 8(4):407-13. PubMed ID: 3020462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral dependence in rhesus monkeys following chronic THC administration.
    Beardsley PM; Balster RL; Harris LS
    NIDA Res Monogr; 1984; 55():111-7. PubMed ID: 6100502
    [No Abstract]   [Full Text] [Related]  

  • 18. [Testing the pharmacological activity of some synthetic cannabinoids in mice (author's transl)].
    Ganz AJ; Waser PG
    Arzneimittelforschung; 1980; 30(3):471-7. PubMed ID: 7387758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of delta 9-THC, the principal psychoactive component of marijuana, during pregnancy in the rhesus monkey.
    Asch RH; Smith CG
    J Reprod Med; 1986 Dec; 31(12):1071-81. PubMed ID: 3025441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral cross-tolerance between repeated intracerebellar nicotine and acute Delta(9)-tetrahydrocannabinol-induced cerebellar ataxia: role of cerebellar nitric oxide.
    Smith AD; Dar MS
    J Pharmacol Exp Ther; 2007 Jul; 322(1):243-53. PubMed ID: 17416741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.